Protagonist Therapeutics Inc (PTGX) is now in the Fair zone, suggesting that its current forward PS ratio of 25.03 is considered Fairly compared with the five-year average of -18.71. The fair price of Protagonist Therapeutics Inc (PTGX) is between 46.87 to 218.01 according to relative valuation method.

Relative Value

Fair Zone

46.87-218.01

Current Price：94.24

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Protagonist Therapeutics Inc (PTGX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Protagonist Therapeutics Inc (PTGX) has a current Price-to-Book (P/B) ratio of 8.43. Compared to its 3-year average P/B ratio of 4.72, the current P/B ratio is approximately 78.57% higher. Relative to its 5-year average P/B ratio of 4.29, the current P/B ratio is about 96.79% higher. Protagonist Therapeutics Inc (PTGX) has a Forward Free Cash Flow (FCF) yield of approximately 1.17%. Compared to its 3-year average FCF yield of -0.15%, the current FCF yield is approximately -864.10% lower. Relative to its 5-year average FCF yield of -5.90%, the current FCF yield is about -119.81% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PTGX competitors is 11.16, providing a benchmark for relative valuation. Protagonist Therapeutics Inc Corp (PTGX.O) exhibits a P/S ratio of 25.03, which is 124.33% above the industry average. Given its robust revenue growth of -95.64%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PTGX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PTGX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PTGX currently overvalued or undervalued?

What is Protagonist Therapeutics Inc (PTGX) fair value?

PTGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Protagonist Therapeutics Inc (PTGX) is between 46.87 to 218.01 according to relative valuation method.

How does PTGX's valuation metrics compare to the industry average?

The average P/S ratio for PTGX's competitors is 11.16, providing a benchmark for relative valuation. Protagonist Therapeutics Inc Corp (PTGX) exhibits a P/S ratio of 25.03, which is 124.33% above the industry average. Given its robust revenue growth of -95.64%, this premium appears unsustainable.

What is the current P/B ratio for Protagonist Therapeutics Inc (PTGX) as of Mar 03 2026?

As of Mar 03 2026, Protagonist Therapeutics Inc (PTGX) has a P/B ratio of 8.43. This indicates that the market values PTGX at 8.43 times its book value.

What is the current FCF Yield for Protagonist Therapeutics Inc (PTGX) as of Mar 03 2026?

As of Mar 03 2026, Protagonist Therapeutics Inc (PTGX) has a FCF Yield of 1.17%. This means that for every dollar of Protagonist Therapeutics Inc's market capitalization, the company generates 1.17 cents in free cash flow.

What is the current Forward P/E ratio for Protagonist Therapeutics Inc (PTGX) as of Mar 03 2026?

As of Mar 03 2026, Protagonist Therapeutics Inc (PTGX) has a Forward P/E ratio of 80.32. This means the market is willing to pay $80.32 for every dollar of Protagonist Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Protagonist Therapeutics Inc (PTGX) as of Mar 03 2026?

As of Mar 03 2026, Protagonist Therapeutics Inc (PTGX) has a Forward P/S ratio of 25.03. This means the market is valuing PTGX at $25.03 for every dollar of expected revenue over the next 12 months.

PTGX Valuation